FDA Approves First Long-Acting Injectable to Prevent HIV Infection
The first long-acting injectable for HIV prevention has now been approved for use, the FDA announced on Monday. Long-acting injectable cabotegravir (CAB-LA, branded as Apretude) is administered as a monthly injection for the first 2 months, then every 2 months afterwards. It is the first long-acting injectable for pre-exposure prophylaxis (PrEP). The drug is approved […]
Long-Acting Injectable for HIV Prevention Passes Hurdles, but Barriers Remain
Long-acting injectable HIV prevention with cabotegravir was superior to daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine (TDF/FTC; Truvada) in men who have sex with men (MSM) and transgender women, a randomized trial found. Among more than 4,500 participants in the phase IIb/III trial, 13 incident infections occurred in the cabotegravir group compared with […]